Peptide sequences used in trial
| Sequence (position) . | Binding to HLA and length of the peptide . |
|---|---|
| WT1-A: RMFPNAPYL* (126-134) | A0201 (9 aa) |
| WT1-A1: YMFPNAPYL† (126-134) (vaccine peptide) | A0201 (9 aa) |
| 427 long: RSDELVRHHNMHQRNMTKL (427-445) (vaccine peptide) | HLA-DR.B1 (19 aa) |
| 331 long: PGCNKRYFKLSHLQMHSRKHTG (331-352) (vaccine peptide) | HLA-DR.B1 (22 aa) |
| 122A long: SGQARMFPNAPYLPSCLES* (122-140) | HLA-DR.B1 (19 aa) |
| 122A1 long: SGQAYMFPNAPYLPSCLES† (122-140) (vaccine peptide) | HLA-DR.B1 (19 aa) |
| Sequence (position) . | Binding to HLA and length of the peptide . |
|---|---|
| WT1-A: RMFPNAPYL* (126-134) | A0201 (9 aa) |
| WT1-A1: YMFPNAPYL† (126-134) (vaccine peptide) | A0201 (9 aa) |
| 427 long: RSDELVRHHNMHQRNMTKL (427-445) (vaccine peptide) | HLA-DR.B1 (19 aa) |
| 331 long: PGCNKRYFKLSHLQMHSRKHTG (331-352) (vaccine peptide) | HLA-DR.B1 (22 aa) |
| 122A long: SGQARMFPNAPYLPSCLES* (122-140) | HLA-DR.B1 (19 aa) |
| 122A1 long: SGQAYMFPNAPYLPSCLES† (122-140) (vaccine peptide) | HLA-DR.B1 (19 aa) |